New frontiers in the treatment of lung cancer

Eva S. Zinreich, R. Robinson Baker, David S Ettinger, Stanley E. Order, James D. Cox

Research output: Contribution to journalArticle

Abstract

Surgical resection still is the only significant curative approach in nonsmall cell lung cancer. Recent surgical experience indicates that a modest decrease in the death rate from bronchogenic carcinoma may occur in three general areas: (1) the detection and treatment of radiographically occult squamous cell carcinoma; (2) the combination of adjuvant chemotherapy and surgical excision in selected patients with small cell carcinoma; and (3) surgical resection and postop irradiation of patients with hilar and mediastinal lymph node metastases. At the time of diagnosis, 80 to 85% of the patients present with unresectable lung cancer. These patients may benefit from other modalities of therapy, i.e., radiotherapy, chemotherapy, or immunotherapy. Failures following radiotherapy in unresectable nonsmall cell lung cancer are due to (1) distant metastasis, (2) local region failure, and (3) local and distant failure. To increase the local control, new methods of treatment have been tried, such as hyperfractionation of radiotherapy and the use of 131I antiferritin immunoglobulin. The development of effective systemic chemotherapy is necessary to treat metastatic bronchogenic carcinoma. The response rate to chemotherapeutic agents is substantially lower in nonsmall cell carcinoma than in small cell carcinoma. Investigation is ongoing to assess the effectiveness of new antitumor drugs used alone, in combination with other drugs, or combined with other modalities for the treatment of bronchogenic carcinoma.

Original languageEnglish (US)
Pages (from-to)279-308
Number of pages30
JournalCritical Reviews in Oncology/Hematology
Volume3
Issue number4
DOIs
StatePublished - 1985

Fingerprint

Bronchogenic Carcinoma
Lung Neoplasms
Small Cell Carcinoma
Radiotherapy
Non-Small Cell Lung Carcinoma
Neoplasm Metastasis
Drug Therapy
Therapeutics
Adjuvant Chemotherapy
Combination Drug Therapy
Antineoplastic Agents
Immunotherapy
Immunoglobulins
Squamous Cell Carcinoma
Lymph Nodes
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Hematology
  • Oncology
  • Cancer Research

Cite this

New frontiers in the treatment of lung cancer. / Zinreich, Eva S.; Baker, R. Robinson; Ettinger, David S; Order, Stanley E.; Cox, James D.

In: Critical Reviews in Oncology/Hematology, Vol. 3, No. 4, 1985, p. 279-308.

Research output: Contribution to journalArticle

@article{92fb6d2c98e542cfa057fc72a83f26c9,
title = "New frontiers in the treatment of lung cancer",
abstract = "Surgical resection still is the only significant curative approach in nonsmall cell lung cancer. Recent surgical experience indicates that a modest decrease in the death rate from bronchogenic carcinoma may occur in three general areas: (1) the detection and treatment of radiographically occult squamous cell carcinoma; (2) the combination of adjuvant chemotherapy and surgical excision in selected patients with small cell carcinoma; and (3) surgical resection and postop irradiation of patients with hilar and mediastinal lymph node metastases. At the time of diagnosis, 80 to 85{\%} of the patients present with unresectable lung cancer. These patients may benefit from other modalities of therapy, i.e., radiotherapy, chemotherapy, or immunotherapy. Failures following radiotherapy in unresectable nonsmall cell lung cancer are due to (1) distant metastasis, (2) local region failure, and (3) local and distant failure. To increase the local control, new methods of treatment have been tried, such as hyperfractionation of radiotherapy and the use of 131I antiferritin immunoglobulin. The development of effective systemic chemotherapy is necessary to treat metastatic bronchogenic carcinoma. The response rate to chemotherapeutic agents is substantially lower in nonsmall cell carcinoma than in small cell carcinoma. Investigation is ongoing to assess the effectiveness of new antitumor drugs used alone, in combination with other drugs, or combined with other modalities for the treatment of bronchogenic carcinoma.",
author = "Zinreich, {Eva S.} and Baker, {R. Robinson} and Ettinger, {David S} and Order, {Stanley E.} and Cox, {James D.}",
year = "1985",
doi = "10.1016/S1040-8428(85)80034-2",
language = "English (US)",
volume = "3",
pages = "279--308",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "4",

}

TY - JOUR

T1 - New frontiers in the treatment of lung cancer

AU - Zinreich, Eva S.

AU - Baker, R. Robinson

AU - Ettinger, David S

AU - Order, Stanley E.

AU - Cox, James D.

PY - 1985

Y1 - 1985

N2 - Surgical resection still is the only significant curative approach in nonsmall cell lung cancer. Recent surgical experience indicates that a modest decrease in the death rate from bronchogenic carcinoma may occur in three general areas: (1) the detection and treatment of radiographically occult squamous cell carcinoma; (2) the combination of adjuvant chemotherapy and surgical excision in selected patients with small cell carcinoma; and (3) surgical resection and postop irradiation of patients with hilar and mediastinal lymph node metastases. At the time of diagnosis, 80 to 85% of the patients present with unresectable lung cancer. These patients may benefit from other modalities of therapy, i.e., radiotherapy, chemotherapy, or immunotherapy. Failures following radiotherapy in unresectable nonsmall cell lung cancer are due to (1) distant metastasis, (2) local region failure, and (3) local and distant failure. To increase the local control, new methods of treatment have been tried, such as hyperfractionation of radiotherapy and the use of 131I antiferritin immunoglobulin. The development of effective systemic chemotherapy is necessary to treat metastatic bronchogenic carcinoma. The response rate to chemotherapeutic agents is substantially lower in nonsmall cell carcinoma than in small cell carcinoma. Investigation is ongoing to assess the effectiveness of new antitumor drugs used alone, in combination with other drugs, or combined with other modalities for the treatment of bronchogenic carcinoma.

AB - Surgical resection still is the only significant curative approach in nonsmall cell lung cancer. Recent surgical experience indicates that a modest decrease in the death rate from bronchogenic carcinoma may occur in three general areas: (1) the detection and treatment of radiographically occult squamous cell carcinoma; (2) the combination of adjuvant chemotherapy and surgical excision in selected patients with small cell carcinoma; and (3) surgical resection and postop irradiation of patients with hilar and mediastinal lymph node metastases. At the time of diagnosis, 80 to 85% of the patients present with unresectable lung cancer. These patients may benefit from other modalities of therapy, i.e., radiotherapy, chemotherapy, or immunotherapy. Failures following radiotherapy in unresectable nonsmall cell lung cancer are due to (1) distant metastasis, (2) local region failure, and (3) local and distant failure. To increase the local control, new methods of treatment have been tried, such as hyperfractionation of radiotherapy and the use of 131I antiferritin immunoglobulin. The development of effective systemic chemotherapy is necessary to treat metastatic bronchogenic carcinoma. The response rate to chemotherapeutic agents is substantially lower in nonsmall cell carcinoma than in small cell carcinoma. Investigation is ongoing to assess the effectiveness of new antitumor drugs used alone, in combination with other drugs, or combined with other modalities for the treatment of bronchogenic carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0022351312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022351312&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(85)80034-2

DO - 10.1016/S1040-8428(85)80034-2

M3 - Article

C2 - 2996797

AN - SCOPUS:0022351312

VL - 3

SP - 279

EP - 308

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 4

ER -